INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ All subjects will be in good general health and    │ All subjects will be in good general health and    │     100 │
│ able to participate in the LP and imaging exams.   │ able to participate in the LP and imaging exams.   │         │
│ This determination is made by the study            │ This determination is made by the study            │         │
│ neurologist and reviewed at a consensus meeting    │ neurologist and reviewed at a consensus meeting    │         │
│ for each subject                                   │ for each subject                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled hypertension or metabolic disease     │ Uncontrolled hypertension or metabolic disease     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Neurodegenerative disorders (i.e. Parkinson        │ Neurodegenerative disorders (i.e. Parkinson        │     100 │
│ disease. LBD, or FTD)                              │ disease. LBD, or FTD)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Long-life DSM-IV axis 1 disorders                  │ Long-life DSM-IV axis 1 disorders                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mental retardation                                 │ Mental retardation                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Substance abuse                                    │ Substance abuse                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent medication limiting validity of         │ Concurrent medication limiting validity of         │     100 │
│ neuropsychological tests or imaging                │ neuropsychological tests or imaging                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anti-depressants with anti-cholinergic properties  │ Anti-depressants with anti-cholinergic properties  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Monoamine oxidase inhibitors (MAOi)                │ Monoamine oxidase inhibitors (MAOi)                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of neuroleptics                                │ Use of neuroleptics                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Individuals taking over the counter memory         │ Individuals taking over the counter memory         │     100 │
│ enhancing or protecting medications (e.g. ginkgo   │ enhancing or protecting medications (e.g. ginkgo   │         │
│ biloba, vitamins) are not excluded                 │ biloba, vitamins) are not excluded                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Implanted medical devices that are incompatible    │ Implanted medical devices that are incompatible    │     100 │
│ with MRI imaging                                   │ with MRI imaging                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Radiation exposures exceeding annual Rad Worker    │ Radiation exposures exceeding annual Rad Worker    │     100 │
│ limits                                             │ limits                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Heart failure stage D as defined by American Heart │ Heart failure stage D as defined by American Heart │     100 │
│ Association (7)                                    │ Association (7)                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Brain tumor and other neoplastic disorders outside │ Brain tumor and other neoplastic disorders outside │     100 │
│ the brain where disease itself or its treatment    │ the brain where disease itself or its treatment    │         │
│ (radiation, chemotherapy) is likely to affect      │ (radiation, chemotherapy) is likely to affect      │         │
│ brain structure or function                        │ brain structure or function                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stroke when meeting criteria for total anterior,   │ Stroke when meeting criteria for total anterior,   │     100 │
│ partial anterior or posterior circulation infarct  │ partial anterior or posterior circulation infarct  │         │
│ according to the Oxford Community Stroke Project   │ according to the Oxford Community Stroke Project   │         │
│ classification. Patients with clinically silent of │ classification. Patients with clinically silent of │         │
│ lacunar strokes and transient ischemic attacks     │ lacunar strokes and transient ischemic attacks     │         │
│ will not be excluded                               │ will not be excluded                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant head trauma                            │ Significant head trauma                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hydrocephalus                                      │ Hydrocephalus                                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hostility or refusal to cooperate                  │ Hostility or refusal to cooperate                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male and female subjects between 20-100 years old  │ Male and female subjects between 40-85 years old   │      98 │
│ will be enrolled. Younger subjects are not         │ will be enrolled. Younger subjects are not         │         │
│ included as the risk for brain amyloid lesions is  │ included as the risk for brain amyloid lesions is  │         │
│ too low                                            │ too low                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Regular use of narcotic analgesics (\>2 doses per  │ Regular use of narcotic analgesics (>2 doses per   │      99 │
│ week)                                              │ week)                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic kidney disease in stages ≥ 4, as defined   │ Chronic kidney disease in stages = 4, as defined   │      99 │
│ per National Kidney Foundation (8)                 │ per National Kidney Foundation (8)                 │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 100 Years                 │ Substance abuse                                    │      37 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 20 Years                  │ Substance abuse                                    │      38 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Person's participating in other research projects  │ Stroke when meeting criteria for total anterior,   │      42 │
│ will be excluded when the other project(s) 1)      │ partial anterior or posterior circulation infarct  │         │
│ involve radiation exposure which in combination    │ according to the Oxford Community Stroke Project   │         │
│ with the current project would increase radiation  │ classification. Patients with clinically silent of │         │
│ exposure above federal guidelines, 2) involve      │ lacunar strokes and transient ischemic attacks     │         │
│ administration of study drug or other experimental │ will not be excluded                               │         │
│ therapy, or 3) prohibit participation in other     │                                                    │         │
│ research projects                                  │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants in this study will be allowed to      │ All subjects will be in good general health and    │      43 │
│ participate in other observational research        │ able to participate in the LP and imaging exams.   │         │
│ studies. The investigators will review at          │ This determination is made by the study            │         │
│ enrollment the full array of projects a subject    │ neurologist and reviewed at a consensus meeting    │         │
│ may be involved in and inform the other PI's to    │ for each subject                                   │         │
│ ensure that subject safety and research data       │                                                    │         │
│ integrity is not compromised                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Person's receiving chronic anti-coagulation        │ Anti-depressants with anti-cholinergic properties  │      44 │
│ therapy                                            │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All subjects may have normal cognition or          │ Dementia or Mild cognitive impairment at baseline  │      54 │
│ cognitive impairment                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All subjects will speak English as their first     │ All subjects will speak English as their first     │      72 │
│ language or demonstrate proficiency in English     │ language or demonstrate proficiency in English     │         │
│                                                    │ (defined as reaching a scaled score of > 11 on the │         │
│                                                    │ WAIS vocabulary test)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Long life major depression. Baseline scores ≥20 on │ Long life major depression. Baseline scores =16 on │      79 │
│ Beck Depression Inventory at baseline              │ the 17-item Hamilton Depression Scale at baseline  │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Individuals taking over the counter memory         │ Use of anti-dementia medications (Aricept, Exelon, │      41 │
│ enhancing or protecting medications (e.g. ginkgo   │ Razadyne) and memantine (Namenda)) or anti-        │         │
│ biloba, vitamins) are not excluded                 │ Parkinsonian medications (Sinemet, amantadine,     │         │
│                                                    │ bromocriptine, pergolide, selegeline)              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All subjects may have normal cognition or          │ All subjects will have normal cognition at         │      52 │
│ cognitive impairment                               │ baseline: a Clinical Dementia Rating CDR=0, Global │         │
│                                                    │ Deterioration Scale GDS<2                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All subjects may have normal cognition or          │ Dementia or Mild cognitive impairment at baseline  │      54 │
│ cognitive impairment                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ All subjects will speak English as their first     │ All subjects will speak English as their first     │      72 │
│ language or demonstrate proficiency in English     │ language or demonstrate proficiency in English     │         │
│                                                    │ (defined as reaching a scaled score of > 11 on the │         │
│                                                    │ WAIS vocabulary test)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Long life major depression. Baseline scores ≥20 on │ Long life major depression. Baseline scores =16 on │      79 │
│ Beck Depression Inventory at baseline              │ the 17-item Hamilton Depression Scale at baseline  │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 76
Average Levenshtein Ratio of individual lines: 82.94285714285714
OverAll Ratio: 79.47142857142856
